Roche announces retirement of senior executives Hans Clevers, Barbara Schadler
Basel: Roche has announced the upcoming retirement of two senior executives, Hans Clevers, Head of Pharma Research and Early Development (pRED), and Barbara Schädler, Head of Group Communications. Both are members of the company’s enlarged Corporate Executive Committee.
Hans Clevers joined the Roche Board of Directors in 2019 and then was appointed Head of Roche pRED in March 2022. Clevers will step down from his current role at the end of August but will continue to lead the Roche Institute of Human Biology until a successor is named.
Roche CEO Thomas Schinecker said, “Hans is an exceptional scientist who has been instrumental in translating cutting-edge science into improved patient outcomes. Under his leadership, the pRED organisation has accelerated several potentially transformational medicines into the final phase of development that will shape the company for the years to come. It has been a pleasure working with him and I am thankful for his many contributions to our company and patients. While he will step down from his current role at the end of August, I am grateful that he will continue to lead our Institute of Human Biology until a successor is announced.”
Barbara Schädler will retire from the company at the end of the year. Barbara Schädler joined Roche in 2019.
Thomas Schinecker continued, “During more than six years at Roche, Barbara Schädler has fully integrated and modernised our company’s communication function. Communications is a core pillar representing who we are as Roche. Through Barbara’s expertise and leadership, she has successfully represented our company both internally and externally. Her resilience and determination were especially evident in her leadership during the COVID-19 pandemic when she championed our internal taskforce. I am thankful for everything that she has achieved and for our excellent collaboration.”
We will announce the successors in due course.
Read also: Roche to proceed with Phase III development of Prasinezumab in early-stage Parkinson's disease
